EUROAPI, a pharmaceutical company has recently revealed its plans to invest €50 million in a new state-of-the-art production plant at its Budapest site. The investment aims to enhance the company's manufacturing capabilities and meet the growing demand for its products
Features:
The investment aims to expand the facility's capacity and meet the growing demand for prostaglandins.
The project will involve debottlenecking the current capacity and constructing new multi-purpose manufacturing equipment.
Prostaglandins are a dynamic component of the API market, with an annual sales market of approximately €5 billion.
EUROAPI is the only Western supplier with a complete portfolio of prostaglandins and a fully integrated production site in Europe.
The investment reinforces EUROAPI's commitment to serving the needs of clients in differentiated health product segments.
The new facility will reduce environmental impact through a modern air handling system, energy-efficient design, and closed waste handling.
It will also feature highly potent-API (HP-API) capabilities for potential future developments.
The prostaglandin market is projected to grow at a CAGR of 5-7% between 2022 and 2027.
The overall prostaglandin capacity of the Budapest site is expected to more than double by 2027.
The investment will be implemented in two phases: 2023-2025 and 2026-2027.
Specifications:
Name: EUROAPI
Type: Expansion
Year: 2026-2027
